Key Takeaways
- Cathie Wood’s ARK Invest offloaded 182,767 shares of Strata Critical Medical on April 13, 2026, valued at approximately $738,378 across two funds
- This sale continues a recent trend, with ARK dumping over 75,000 additional shares on April 10
- The company operates a specialized organ transplant logistics network serving U.S. healthcare facilities
- Wall Street analysts have recently launched coverage with bullish Buy ratings and $8 price targets
- Consensus analyst forecasts point to a price target of $9.08, representing more than 120% potential gains from current levels near $4.12
Over recent trading sessions, Cathie Wood’s investment firm ARK Invest has been methodically trimming its stake in Strata Critical Medical. The latest transaction occurred on April 13, 2026, when ARK disposed of 182,767 shares via the ARK Autonomous Technology & Robotics ETF and the ARK Space Exploration & Innovation ETF. The total transaction value came to roughly $738,378.
Strata Critical Medical, Inc., SRTA
This divestment wasn’t an isolated incident. Earlier in the week, on April 10, ARK unloaded more than 75,000 shares, with additional sales recorded on several other occasions during this timeframe. The consistent selling activity suggests a strategic repositioning away from the healthcare logistics firm.
Strata Critical Medical operates as a specialized healthcare logistics provider with a small-cap market footprint. The company manages one of America’s most extensive air transportation and surgical support networks dedicated to organ transplant procedures. Management positions the firm as the sole comprehensive end-to-end solution provider in the organ transplant logistics sector.
Currently, shares are changing hands at approximately $4.12. The stock registered a 2% increase on April 13 and has climbed 51% over the trailing twelve months, keeping it within penny stock range.
Wall Street Remains Optimistic Amid ARK’s Retreat
Contrary to ARK‘s divestment strategy, a pair of Wall Street analysts have recently launched coverage with optimistic outlooks.
Yuan Zhi from B. Riley Securities initiated coverage with a Buy recommendation and set an $8 price objective. Zhi highlighted the company’s dominant position within the U.S. organ transplant sector and emphasized its unique standing as the sole end-to-end logistics platform in this specialized niche.
Meanwhile, Craig-Hallum’s Bill Bonello also started coverage with a Buy rating alongside an $8 target. Bonello noted that while the company has undergone significant transformations over the last year, the stock’s current valuation hasn’t yet captured the improved growth trajectory.
Both research analysts anticipate that market sentiment will strengthen as the company delivers more transparent financial performance data.
Analyst Consensus and Price Projections
According to TipRanks, Strata Critical Medical carries a Strong Buy consensus rating, supported by three unanimous Buy recommendations from analysts.
The consensus price objective stands at $9.08, indicating potential appreciation exceeding 120% from the present trading level of approximately $4.12.
Bonello further suggested that existing Wall Street estimates may be understated, hinting at the possibility of even greater upside than current projections indicate.
ARK Invest has not disclosed specific reasons behind its continued share sales, and no new purchases were documented on April 13.
Shares concluded trading at $4.12 on April 13, 2026, with all three covering analysts maintaining Buy ratings and a consensus target of $9.08.
